PEDIATRIX MEDICAL GROUP INC (MD) Fundamental Analysis & Valuation

NYSE:MD • US58502B1061

Current stock price

21.45 USD
+0.11 (+0.52%)
At close:
21.45 USD
0 (0%)
After Hours:

This MD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. MD Profitability Analysis

1.1 Basic Checks

  • In the past year MD was profitable.
  • In the past year MD had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
  • Each year in the past 5 years MD had a positive operating cash flow.
MD Yearly Net Income VS EBIT VS OCF VS FCFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B

1.2 Ratios

  • With an excellent Return On Assets value of 7.36%, MD belongs to the best of the industry, outperforming 87.00% of the companies in the same industry.
  • With an excellent Return On Equity value of 19.10%, MD belongs to the best of the industry, outperforming 86.00% of the companies in the same industry.
  • MD has a Return On Invested Capital of 9.88%. This is in the better half of the industry: MD outperforms 80.00% of its industry peers.
  • MD had an Average Return On Invested Capital over the past 3 years of 8.21%. This is in line with the industry average of 8.74%.
  • The last Return On Invested Capital (9.88%) for MD is above the 3 year average (8.21%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROIC 9.88%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
MD Yearly ROA, ROE, ROICMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80 -100

1.3 Margins

  • MD has a better Profit Margin (8.64%) than 91.00% of its industry peers.
  • MD's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 12.07%, MD belongs to the best of the industry, outperforming 84.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of MD has grown nicely.
Industry RankSector Rank
OM 12.07%
PM (TTM) 8.64%
GM N/A
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MD Yearly Profit, Operating, Gross MarginsMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. MD Health Analysis

2.1 Basic Checks

  • MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, MD has less shares outstanding
  • Compared to 5 years ago, MD has less shares outstanding
  • MD has a better debt/assets ratio than last year.
MD Yearly Shares OutstandingMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
MD Yearly Total Debt VS Total AssetsMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • MD has an Altman-Z score of 2.07. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • MD has a Altman-Z score (2.07) which is in line with its industry peers.
  • The Debt to FCF ratio of MD is 2.36, which is a good value as it means it would take MD, 2.36 years of fcf income to pay off all of its debts.
  • MD has a better Debt to FCF ratio (2.36) than 74.00% of its industry peers.
  • A Debt/Equity ratio of 0.66 indicates that MD is somewhat dependend on debt financing.
  • MD has a Debt to Equity ratio (0.66) which is in line with its industry peers.
  • Even though the debt/equity ratio score it not favorable for MD, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Altman-Z 2.07
ROIC/WACC1.18
WACC8.4%
MD Yearly LT Debt VS Equity VS FCFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • MD has a Current Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Current ratio value of 1.66, MD is doing good in the industry, outperforming 69.00% of the companies in the same industry.
  • A Quick Ratio of 1.66 indicates that MD should not have too much problems paying its short term obligations.
  • MD has a Quick ratio of 1.66. This is in the better half of the industry: MD outperforms 70.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
MD Yearly Current Assets VS Current LiabilitesMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 36.24% over the past year.
  • Measured over the past years, MD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.01% on average per year.
  • The Revenue has decreased by -4.92% in the past year.
  • The Revenue has been growing slightly by 1.99% on average over the past years.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%

3.2 Future

  • Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 0.99% on average per year.
  • The Revenue is expected to grow by 3.93% on average over the next years.
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MD Yearly Revenue VS EstimatesMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
MD Yearly EPS VS EstimatesMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. MD Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 10.57, the valuation of MD can be described as reasonable.
  • MD's Price/Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 92.00% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of MD to the average of the S&P500 Index (26.78), we can say MD is valued rather cheaply.
  • The Price/Forward Earnings ratio is 9.32, which indicates a very decent valuation of MD.
  • MD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 93.00% of the companies in the same industry.
  • MD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.54.
Industry RankSector Rank
PE 10.57
Fwd PE 9.32
MD Price Earnings VS Forward Price EarningsMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 88.00% of the companies in the same industry are more expensive than MD, based on the Enterprise Value to EBITDA ratio.
  • MD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MD is cheaper than 90.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.05
EV/EBITDA 6.9
MD Per share dataMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.79
PEG (5Y)1.06
EPS Next 2Y8.67%
EPS Next 3Y4.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MD Dividend Analysis

5.1 Amount

  • MD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MD Fundamentals: All Metrics, Ratios and Statistics

PEDIATRIX MEDICAL GROUP INC

NYSE:MD (4/10/2026, 8:04:00 PM)

After market: 21.45 0 (0%)

21.45

+0.11 (+0.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19
Earnings (Next)04-30
Inst Owners102.64%
Inst Owner Change0%
Ins Owners1.94%
Ins Owner Change-0.8%
Market Cap1.78B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.76 (1.45%)
Short Float %3.74%
Short Ratio3.47
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)-0.78%
PT rev (3m)-5.88%
EPS NQ rev (1m)-0.75%
EPS NQ rev (3m)-1.3%
EPS NY rev (1m)2.14%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)-1.59%
Revenue NY rev (3m)-1.59%
Valuation
Industry RankSector Rank
PE 10.57
Fwd PE 9.32
P/S 0.93
P/FCF 7.05
P/OCF 6.57
P/B 2.06
P/tB N/A
EV/EBITDA 6.9
EPS(TTM)2.03
EY9.46%
EPS(NY)2.3
Fwd EY10.73%
FCF(TTM)3.04
FCFY14.19%
OCF(TTM)3.27
OCFY15.23%
SpS23.06
BVpS10.43
TBVpS-4.96
PEG (NY)0.79
PEG (5Y)1.06
Graham Number21.83
Profitability
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROCE 12.93%
ROIC 9.88%
ROICexc 13.71%
ROICexgc 1686.9%
OM 12.07%
PM (TTM) 8.64%
GM N/A
FCFM 13.2%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Debt/EBITDA 2.26
Cap/Depr 84.57%
Cap/Sales 0.96%
Interest Coverage 6.72
Cash Conversion 107.19%
Profit Quality 152.75%
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z 2.07
F-Score8
WACC8.4%
ROIC/WACC1.18
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.33%
EBIT Next 3Y6.84%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%

PEDIATRIX MEDICAL GROUP INC / MD Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?

ChartMill assigns a fundamental rating of 6 / 10 to MD.


Can you provide the valuation status for PEDIATRIX MEDICAL GROUP INC?

ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.


Can you provide the profitability details for PEDIATRIX MEDICAL GROUP INC?

PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.


Can you provide the financial health for MD stock?

The financial health rating of PEDIATRIX MEDICAL GROUP INC (MD) is 6 / 10.